Stockwinners Market Radar for February 06, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EST Innophos Holdings trading halted, pending information request

19:09 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: Telenav (TNAV) up 23.4%... Pinterest (PINS) up 17.6%... Synaptics (SYNA) up 17.0%... Skechers (SKX) up 13.3%... eGain Corp (EGAN) up 10.8%... 2U (TWOU) up 8.6%... DXC Technology (DXC) up 7.3%... Bill.com (BILL) up 7.2%... NortonLifeLock (NLOK) up 6.9%... Uber (UBER) up 4.6%... Silicon Motion (SIMO) up 3.2%... Viasat (VSAT) up 3.0%... Carlisle (CSL) up 2.6%... Activision Blizzard (ATVI) up 2.5%... Ligand Pharma (LGND) up 2.4%... Virtusa (VRTU) up 2.1%... MEI Pharma (MEIP) up 1.4%... Lions Gate (LGF) up 1.2%... T-Mobile (TMUS) up 0.9%. ALSO HIGHER: Collegium Pharma (COLL) up 8.4% after acquiring U.S. rights to Nucynta. DOWN AFTER EARNINGS: Myriad Genetics (MYGN) down 29.5%... LeMaitre Vascular (LMAT) down 14.8%... Take-Two Interactive (TTWO) down 8.3%... Pixelworks (PXLW) down 7.7%... MobileIron (MOBL) down 7.4%... Seattle Genetics (SGEN) down 5.4%... FleetCor Tech (FLT) down 4.8%... Teradata (TDC) down 4.5%... Trinseo (TSE) down 4.0%... Mettler-Toledo (MTD) down 3.7%... Forward Air (FWRD) down 3.6%... Columbia Sportswear (COLM) down 3.4%... Zendesk (ZEN) down 3.2%... Aviat Network (AVNW) down 3.0%... Wynn Resorts (WYNN) down 1.2%. ALSO LOWER: Miragen Therapeutics (MGEN) down 24.2% after equity offering. Movers as of 18:30ET.

18:25 EST Cigna CEO: We're producing a phenomenal amount of operating cash flow - In an interview on CNBC's Mad Money, David Cordani said, "The Express Scripts acquisition is working really well. We are producing a phenomenal amount of operating cash flow." Cordani noted the company's customer base is growing rapidly and should reach 200M soon. He said, "We're managing one customer and one physician at a time." When asked how prepared the U.S. is to combat the coronavirus, Cordani added, "We're as ready as any developed country can be."

17:54 EST Charter director sells 940 shares of common stock - In a regulatory filing, Charter disclosed that its director Craig Jacobson sold 940 shares of common stock on February 4th. The total transaction size was $498K.

17:38 EST DXC says has material weakness in internal controls

17:28 EST Pinterest up 17% to $27.00 after Q4 results, FY20 guidance top estimates

17:26 EST Silvercorp Metals expects to process 930K-970K tons of ore in FY21 - FY21 production guidance would yield 6.2 million to 6.5 million ounces of silver, 66.1 million to 68.5 million pounds of lead, and 24.5 million to 26.7 million pounds of zinc. FY21 production guidance represents an increase of approximately 2% to 7% in silver production, 2% to 5% in lead production, and 12% to 22% in zinc production compared to the current FY20 annual guidance. Cash production costs are expected to be $74.7 to $82.5 per ton of ore, and the all-in sustaining costs are estimated at $133.5 to $140.5 per ton of ore processed.

17:11 EST Netflix adds feature to control autoplay - The company said in a tweet, "Some people find this feature helpful. Others not so much. We've heard the feedback loud and clear - members can now control whether or not they see autoplay" Reference Link

17:08 EST Plus Therapeutics announces Greg Petersen joining board - Plus Therapeutics,announced that Greg Petersen has joined the Company's Board of Directors to serve as an independent director, effective February 14. Greg will serve on the Audit and Compensation Committees. In addition, on January 31, 2020, Gregg Lapointe, submitted his resignation from the board of directors."We are happy that Greg Petersen has agreed to join our Board of Directors," said Dr. Marc Hedrick, President and CEO of Plus Therapeutics. "Greg is a seasoned public company Chief Financial Officer and board member having served those positions for a number of high growth companies over his career. More specifically, Greg has extensive experience in both audit and compensation matters and will serve on both of these committees on our Board of Directors."

17:04 EST Activision Blizzard says committed to updating 'Warcraft 3' remake going forward - Says has been "a bit of a hard week" when it comes to "Warcraft 3: Reforged." Says heard from fanbase that company did not achieve lofty goal of remaking "Warcraft 3" properly. Says committed to updating and rebuilding the game going forward.

17:03 EST Deutsche Bank appointed successor depositary bank for AstraZeneca ADR program - Deutsche Bank (DB) announced its appointment as successor depositary bank for the sponsored American Depositary Receipt Program of AstraZeneca (AZN).

17:00 EST Myriad Genetics shares plunge 30% amid CEO transition, Q2 results - Shares of Myriad Genetics are down 30% or almost $9.00 per share to $20.55 per share in post market trading.

16:56 EST Activision Blizzard says entered 2020 with 'strong momentum' for 'COD' - Says enters year with "strong momentum" for "Call of Duty." Says "encouraged" by 2019 results. Says will maintain operating discipline going forward.

16:55 EST Take-Two's "The Outer Worlds" Switch port delayed due to coronavirus - Take-Two's (TTWO) Private Division said via Twitter that it is delaying the port of its game "The Outer Worlds" on Nintendo Switch (NTDOY) due to the coronavirus impacting the Virtuos team working on the port, to provide them enough time to finish development. "We'll now be releasing the physical version on cartridge," the company said. "Once we have a new launch date, we'll let you know!" "The Outer Worlds" is currently available on PC, Xbox One (MSFT), and PlayStation 4 (SNE). Reference Link

16:47 EST Ryman Hospitality announces $80M, $317-room expansion of Gaylord Rockies - Ryman Hospitality announced plans for an $80M, 317-room expansion of Gaylord Rockies Resort & Convention Center in Aurora, Colorado. Opened in December 2018, Gaylord Rockies was the first Marriott property to begin operations with more than 1M net room nights on the books for all future years. Since that time, the 85-acre resort has experienced strong demand and closed Q3 with nearly 1.2M net group room nights on the books for all future years, a 7.4% increase compared to Q3. Construction is expected to begin in Q2 and the expansion is expected to open in early 2022. Once complete, the expansion will bring the total room count at Colorado's largest combined resort and convention center to 1,818.

16:46 EST Therapix Biosciences granted extension to regain Nasdaq listing compliance - Therapix Biosciences received notice that the Nasdaq Hearings Panel granted the company an extension until April 1 to regain compliance with the minimum $2.5B stockholders' equity requirement for continued listing on Nasdaq. The Panel's decision follows the hearing at which Therapix's management presented the Panel with a plan for regaining and sustaining compliance with the Stockholders' Equity Requirement.

16:45 EST Aurora Cannabis trading resumes

16:44 EST Aurora Cannabis sees Q2 cannabis revenues $62M-$66M - Aurora provided unaudited preliminary second quarter fiscal 2020 financial results. The Company expects cannabis revenues for the second quarter of fiscal 2020 of $62 million to $66 million, net of excise taxes. Aurora expects to record provisions for returns, price reductions and future provisions of approximately $12 million, almost all of which relates to product sold in previous quarters. Therefore, net cannabis revenues, after giving effect to these offsets, are expected to be $50 million to $54 million. These revenue expectations reflect consistent quarter-over-quarter medical revenues, a decrease in international revenues due to short-term German supply interruptions, and much lower bulk sales. For the second quarter, Aurora expects to report modest quarter-over-quarter growth in consumer cannabis revenues prior to applying these offsetting return and price reduction allowances. Cash cost to produce per gram of dried cannabis sold is expected to remain below $1.00, sales and marketing expenses are expected to be between $28 million to $32 million and general and administrative expenses are expected to be between $70 million to $75 million. The outlook for cannabis revenue for Aurora's fiscal third quarter is expected to be impacted by the general industry headwinds mentioned above, and as such will likely show little to no growth relative to fiscal Q2's cannabis revenue of $62 million to $66 million, prior to the provisions for returns and price reductions.

16:43 EST Aurora Cannabis undertakes review of all business operations - Aurora announced that, given market current cannabis market conditions and the slower than expected near-term industry growth, it has undertaken a thorough review of all business operations and concluded that certain assets and goodwill values as at December 31, 2019 exceed current fair-market valuations. As such, when Aurora formally reports its fiscal second quarter 2020 results, it expects to report asset impairment charges on certain intangible and property, plant and equipment in a range of $190 million to $225 million and write-downs of goodwill in the range of $740 million to $775 million. Following these non-cash charges, Aurora expects to remain compliant with its revised total debt-to-equity covenant going forward. Aurora announced that its consolidated cash position was $156 million, excluding $45 million of restricted cash as at December 31, 2019. This includes gross proceeds raised under its US$400 million At-the-Market financing program of approximately US$245 million to date in fiscal 2020. As of today, the Company has remaining capacity under its current ATM program of approximately $200 million. With the cost reduction and business transformation initiatives announced today, the Company expects that utilization of the ATM capacity will be sufficient to fund operations and remaining required capital expenditures, to the points where positive EBITDA and free cash flow are achieved.

16:42 EST Aurora Cannabis to reduce CapEx for 2H20 to bring CapEx below $100M

16:42 EST Uber seeing consecutive sequential margin improvement - Targets 25% adjusted EBITDA margin over long term. Sees sufficient liquidity position to reach profitability in 2021. Comments taken from investor presentation slides accompanying Q4 results. Reference Link

16:41 EST Azul reports January traffic up 29.1%, capacity up 26.5% - Load factor of 85.2% was 1.7 percentage points higher than the same period in 2019. Domestic load factor was 84.4% and international load factor was 87.8%.

16:40 EST Amtech Systems receives new order for 300mm clustered HTR diffusion furnace - Amtech Systems announced that its subsidiary, Bruce Technologies, has received a significant new order for its full 300mm clustered HTR diffusion furnace from a top-tier global power semiconductor customer in Asia. The furnace is expected to ship in fiscal Q1 2021.

16:39 EST Uber CEO aiming to accelerate positive EBITDA target to Q4 of 2020 from 2021 - Says 'excited to sharpen focus on execution' to gain 'massive scale'. Comments taken from Q4 earnings conference call.

16:37 EST CBIZ acquires Pension Dynamics Company, terms not disclosed - CBIZ announced the acquisition of substantially all the assets of Pension Dynamics Company of Pleasant Hill, CA, effective February 1. PD, founded by Stephen Butler in 1979, is a full-service retirement and benefits plan advisor providing a wide array of plans including 401(k), 403(b), 457(b), defined benefit, cash balance, profit sharing, and flex, COBRA, health reimbursement and commuter plans to clients in the San Francisco Bay area. PD has 25 employees and approximately $3.6M in annual revenue.

16:33 EST Asur reports total January passenger traffic up 7.8% - Asur announced that total passenger traffic for January 2020 increased 7.8% when compared to January 2019. Passenger traffic increased 6.2% in Mexico, 11.4% in Puerto Rico and 9.3% in Colombia.

16:30 EST IntercontinentalExchange ceases exploring opportunities with eBay - Intercontinental Exchange (ICE) is sharing the following statement: Based on investor conversations following today's ICE earnings call, ICE has decided to cease exploring strategic opportunities with eBay (EBAY).

16:30 EST Collegium Pharmaceutical trading resumes

16:28 EST Hawaiian Airlines reports January traffic up 6.6%, capacity up 7.5% - Load factor was down 0.7 pts to 83.6%.

16:26 EST Verizon authorizes 100M share repurchase - The board of Verizon authorized the corporation to repurchase up to 100M shares of its common stock. Verizon's previous program, which expires on February 29, also authorized the repurchase of 100M shares. Under the prior authorization, no shares were repurchased. The new authorization supersedes the prior authorization, and no additional shares of common stock of the corporation will be repurchased under the prior authorization. The new program will terminate upon the earlier of the date on which the aggregate number of shares purchased reaches 100M, or the authorization of another share repurchase plan that supersedes the current plan.

16:25 EST FTS International receives continue listing standard notice from NYSE - FTS International, Inc. announced it has received written notice from the New York Stock Exchange notifying it that, over a period of 30 consecutive trading days, the average closing price of the Company's common stock was below the minimum $1.00 per share requirement for continued listing on the NYSE under Item 802.01C of the NYSE Listed Company Manual. In accordance with applicable NYSE procedures, the Company plans to timely notify the NYSE that it intends to cure the $1.00 per share deficiency and has six months following the receipt of the noncompliance notice to cure the deficiency and regain compliance with the NYSE continued listing requirement. The notice has no immediate impact on the listing of the Company's common stock, which will continue to trade on the NYSE. The Company intends to actively monitor the closing share price for its common stock and will explore available options to regain compliance.

16:24 EST Encompass Health backs FY20 adjusted EBITDA view $935M-$965M

16:20 EST Amtech Systems renews share repurchase plan for up to $4M - Board of Directors approval to renew share repurchase program of up to $4M of outstanding common stock, effective for the next 12 months

16:18 EST Net 1 UEPS replenishes repurchase authorization back to $100M - Net 1 UEPS said that on February 5, 2020, its Board of Directors replenished the authorization to repurchase up to $100M of its common shares. The authorization does not have an expiration date. The share repurchase authorization will be used at management's discretion, subject to legal requirements and price and other internal limitations established by our board of directors.

16:17 EST Myriad Genetics CEO Mark Capone resigns, Bryan Riggsbee named interim CEO - Myriad Genetics announced today that R. Bryan Riggsbee, CFO, has been appointed interim president and CEO effective immediately and will also continue to serve as CFO. Mark Capone has resigned as President and CEO and as a member of the company's board, effective immediately. Capone will remain available to the company to assist in this transition.

16:15 EST Skechers CEO says monitoring coronavirus situation in China - CEO Robert Greenberg states: "2019 was a remarkable year for Skechers as we achieved four quarters of record sales. Our continued growth along with the 27 product and brand awards we received in 2019 are evidence that we accomplished our goal. 2019 was also the year we saw the resurgence of chunky sneakers-and as an originator in this category, we became a go-to source around the world. We are deeply concerned by the health crisis in China, and for the well-being of our employees, partners, vendors and consumers in the region. We continue to monitor this situation and its potential disruption to our global business. The Skechers brand is strong in China, and we remain confident in our long-term prospects in the country."

16:07 EST Uber CEO says 2019 'a transformational year' - "2019 was a transformational year for Uber and I'm gratified by our progress, steadily delivering against the commitments we've made to our shareholders on our path to profitability," said Dara Khosrowshahi, CEO. "We recognize that the era of growth at all costs is over. In a world where investors increasingly demand not just growth, but profitable growth, we are well-positioned to win through continuous innovation, excellent execution, and the unrivaled scale of our global platform."

16:06 EST Collegium acquires U.S. rights to Nucynta from Assertio for $375M in cash - Collegium Pharmaceutical (COLL) announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta Franchise from Assertio Therapeutics (ASRT) for $375M in cash."Acquiring the full U.S. rights to the Nucynta Franchise is financially transformative for Collegium," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We expect the acquisition to improve annual EBITDA and operating cash flows by more than $100 million. The transaction is supported by a financing structure that allows for rapid de-leveraging and enables us to pursue future business development transactions." Collegium will make a cash payment to Assertio of $375.0 million, less royalties paid to Assertio in 2020, and subject to certain other adjustments. Collegium will assume the U.S. license for the Nucynta Franchise, and will no longer be required to pay royalties to Assertio. Collegium has secured debt financing commitments of $325.0 million that, together with cash on hand, will be used to fund the purchase price payable to Assertio. Collegium will continue to pay Grunenthal GmbH a flat 14% royalty on net sales of the Nucynta Franchise, but will no longer be required to pay a supplemental royalty on sales greater than $180.0 million.The transaction is expected to be immediately accretive and to significantly increase Collegium's profitability and operating cash flows. The deal is expected to close on February 14, 2020, subject to satisfaction of customary closing conditions.

16:02 EST DBV Technologies names Pascal Wotling as chief technical operations officer - DBV Technologies (DBVT) announced the appointment of Pascal Wotling as its Chief Technical Operations Officer, effective April 1, 2020. Pascal will be responsible for manufacturing, supply chain and new product process development, and will serve as a member of the Executive Committee, reporting to Daniel Tasse, CEO of DBV Technologies. "I am delighted to have Pascal on the team - he's a committed leader bringing two decades of expertise managing complex drug manufacturing operations," said Daniel Tasse. "His experience will be crucial as he drives the execution of our manufacturing strategy, including new product development, to progress our organization to commercialization and help bring our first product to patients, if approved." Pascal will be based in Bagneux, France, and oversee manufacturing, supply chain and new product process development. He most recently served as Head of External Supply Operations, Asia-Pacific, Middle East and Africa in Shanghai for Novartis (NVS).

16:00 EST Assertio Therapeutics trading halted, news pending

15:32 EST Co-Diagnostics announces launch of test for new coronavirus - Co-Diagnostics announced that its research use only CoPrimer test for the 2019-nCoV coronavirus is ready for sale to appropriate laboratories, hospitals, and institutions in need of a solution to the current coronavirus epidemic. "Increased specificity is one of the hallmarks of tests built using our patented CoPrimer platform. Leveraging our proprietary design process and software has allowed us to quickly move this product from design into commercialization, and to do so with the confidence that our high-quality product meets our goal of providing an effective, much-needed global diagnostic solution in an emergency situation. As a result of our rapid development, we have already received requests from customers in countries across the world to purchase tests. Sales and shipments of products will be fulfilled from our Utah headquarters to customers who have the capacity to utilize RUO products to slow the spread of this epidemic...We are already in communication with the FDA regarding clearance of our 2019-nCoV test on an emergency use basis. If approved, it will allow us to commercialize the test as an IVD, reaching even more markets affected by this disease. We are also pursuing a CE marking for the European Union and any country or jurisdiction that allows registration of IVD products that bear a valid CE marking, as well as emergency use clearance in India for our manufacturing joint venture in that country," said Dwight Egan, CEO of Co-Diagnostics.

15:17 EST New York Times raises quarterly dividend to 6c from 5c per share - The dividend is payable on April 23 to shareholders of record as of the close of business on April 8.

14:52 EST Fitch downgrades Macy's Long-Term IDR to 'BBB-' with stable outlook - Fitch Ratings has downgraded Macy's and Macy's Retail Holdings' ratings, including the Long-Term Issuer Default Ratings - IDRs - to 'BBB-' from 'BBB', and Short-Term IDRs to 'F3' from 'F2'. The Rating Outlook is Stable. "The downgrade reflects Fitch's view of a prolonged timeframe for Macy's operating trajectory to stabilize on a lower EBITDA (Fitch does not include asset sale gains in its EBITDA calculations) base. This follows sustained low single digit comparable store sales declines, EBITDA margins well below expectations and increased management urgency to address secular challenges, as evidenced by the announcement of 125 store closures and $1.5 billion in cost reductions to support business reinvestment. Despite initial expectations of EBITDA stabilization in 2019, EBITDA is projected to decline around 13% on a comps decline of approximately 1%. Fitch now expects EBITDA could modestly decline from approximately $2.2 billion in 2019 toward $2.0 billion over the next two to three years given increased investments to combat ongoing secular challenges, including weak mall traffic and heightened competition from alternate channels that include online and off-price," Fitch said.

14:11 EST Barnes & Noble Education holder Outerbridge encouraged by strategic review - In a regulatory filing, Barnes & Noble Education holder Outerbridge, which owns a 13.5% stake in the company, said it is encouraged by the decision of the board of directors to retain Morgan Stanley to assist in its ongoing review of strategic alternatives. Outerbridge believe a strategic review to be a logical avenue for unlocking value for Barnes & Noble Education shareholders, given historical challenges of execution at the Issuer, a fast-changing industry, and an abundance of potential financial and strategic buyers for its business. Since the filing of the initial 13D, Outerbridge has continued to engage in discussions and meetings with BNED's management. Outerbridge has introduced qualified consultants to thecompany with expertise in digital subscription and inclusive access business models - the two initiatives highlighted by management as being most critical to the Issuer's business model transformation. Outerbridge has also introduced to the Issuer a qualified prospective Board member with extensive experience serving on both audit and transaction committees, and a track record of delivering value for shareholders in strategic reviews. Outerbridge is confident that a robust, well-conducted process will yield an acquirer in this active M&A market. The Outerbridge look forward to continuing their engagement with the Issuer as the Board and its financial advisor work to maximize value for all shareholders.

13:46 EST C-Band Alliance calls FCC Chairman comments 'significant development' - The C-Band Alliance, comprised of Intelsat (I), SES (SGBAF) and Telesat, responded to remarks delivered by Federal Communications Commission Chairman Ajit Pai. The Alliance said, "The imminent issuance of the draft order reflects the tireless efforts of many over the past several years to ensure that this critical spectrum comes to market safely, quickly, and efficiently. Today's comments by Chairman Pai are a significant development in this important proceeding. We look forward to reviewing the draft order, once issued, to place Chairman Pai's comments in full context."

13:34 EST Aurora Cannabis trading halted, news pending

13:21 EST Airbus logged net orders in January for 274 commercial aircraft - Airbus said it logged net orders in January for 274 commercial aircraft from its A220, A320 and A350 XWB product lines. During the month, 31 deliveries were made from the A220, A320, A330 and A350 XWB aircraft families. Before cancellations were taken into account, Airbus' gross order total in 2020 was for 296 aircraft as of January 31. Airbus' backlog of aircraft remaining to be delivered as of January 31 stood at 7,725. This total was comprised of 6,249 A320 Family aircraft and 551 A220s, as well as 330 A330s, 586 A350 XWBs and nine A380s.

13:09 EST USITC to investigate Google over Sonos audio player complaint - The U.S. International Trade Commission has voted to institute an investigation of certain audio players and controllers, components thereof, and products containing the same. The products at issue in the investigation are described in the Commission's notice of investigation. The investigation is based on a complaint filed by Sonos (SONO) of Santa Barbara, CA, on January 7, 2020. The complaint alleges violations of section 337 of the Tariff Act of 1930 in the importation into the United States and sale of certain audio players and controllers, components thereof, and products containing the same that infringe patents asserted by the complainant. The complainant requests that the USITC issue a limited exclusion order and cease and desist orders. The USITC has identified Google (GOOG) and Alphabet as respondents in this investigation. By instituting this investigation, the USITC has not yet made any decision on the merits of the case. The USITC's Chief Administrative Law Judge will assign the case to one of the USITC's administrative law judges, who will schedule and hold an evidentiary hearing. The ALJ will make an initial determination as to whether there is a violation of section 337; that initial determination is subject to review by the Commission. Reference Link

13:05 EST FCC posts summary of Chairman Pai's C-band proposal - In a post to its website summarizing FCC Chairman Ajit Pai's draft rules that would reform the use of the C-band and make a large amount of spectrum available for 5G, the FCC stated in part: "Chairman Pai's draft rules would make the lower 280 megahertz of the C-band available for flexible use, including 5G, through a public auction. Existing satellite operations would be repacked into the upper 200 megahertz of the band with relocation costs covered. This strikes the appropriate balance between making available critical mid-band spectrum for 5G and protecting incumbent uses. This would be the Commission's most significant action yet to repurpose mid-band airwaves and would represent a critical step toward securing United States leadership in 5G. It would quickly free up a significant amount of spectrum for next-generation wireless services, and it would generate significant revenue for the U.S. Treasury. The full Commission will vote on this Report and Order on February 28, 2020 at the FCC's Open Meeting...The FCC would hold a public auction of the lower 280 MHz of the C-band...The Commission has the infrastructure in place for an auction to start later this year, and Chairman Pai is proposing that the Commission begin the C-band auction on December 8... Satellite operators and other February 6, 2020 incumbents would be reimbursed by the winning bidders in the C-band auction for reasonable relocation costs...Additionally, satellite operators would have the opportunity to receive accelerated relocation payments if they are able to clear the lower portion of the C-band on an accelerated timeline, thus advancing the national priority of making spectrum available for 5G deployment more quickly. These payments would create powerful incentives for incumbent operators to expedite the transition, and operators would only be paid if in fact they did so. The accelerated payments could total up to $9.7 billion and would be paid by winning bidders in the C-band auction...Under the accelerated timeframe, 5G deployments could happen in the lower 100 megahertz of the Cband in 46 of the nation's top 50 Partial Economic Areas by September 2021 and in the remaining spectrum by September 2023. This is much sooner than September 2025, which would be the timeframe without accelerated relocation payments." Reference Link

13:00 EST Intelsat off earlier highs after FCC Chair presents C-band plan - FCC Chairman Ajit Pai delivered a speech about the next steps in repurposing a large portion of C-band spectrum to fuel 5G deployment. According to FCC Press Secretary Tina Pelkey, Pai's plan frees up a significant amount of C-band spectrum for 5G, "It does so quickly, it generates revenue for the U.S. Treasury and it protects the services that are currently delivered using this spectrum." Bloomberg's coverage of the event, Pai said the plan calls for clearing 280 Mhz and that a public auction is the "best approach" and "best bet to ensure fairness." The auction is planned to start by the end of 2020, on December 8, according to Bloomberg's quotes from Pai. Pai proposed to accelerate payments for satellite operators and said that payments for quickly clearing airwaves can be $9.7B under his plan, Bloomberg added. In volatile afternoon trading, Intelsat shares are now up 17c, or roughly 5%, to $3.89, well off the highs seen earlier in the session.

12:40 EST MeetMe trading resumes

12:13 EST L'Oreal says coronavirus will have temporary impact on beauty market - The company said in its earnings release, "The coming weeks will certainly be challenging for the people of China in their battle against the coronavirus epidemic, and we want to convey our deepest solidarity with them. We are of course fully supportive and united with our Chinese teams, and are carefully monitoring the situation. We trust the Chinese authorities to take effective and appropriate measures to best contain this epidemic. This context will have a temporary impact on the beauty market in the region and therefore on our business in China and Travel Retail Asia, even if it is too early to assess it. The experiences we have had with similar situations in the past (SARS, MERS, etc.) show that, after a period of disturbance, consumption resumes stronger than before. Therefore, at this stage, and assuming that this epidemic follows a similar pattern, we are confident in our capacity this year again to outperform the beauty market and achieve another year of growth in both sales and profits."

12:00 EST Unisys rises 41.3% - Unisys is up 41.3%, or $4.58 to $15.68.

11:46 EST Amazon plans to create 15,000 jobs in Bellevue, expanding presence in city - In an earlier posting to its Day One blog, Amazon announced earlier on Thursday: "We opened our first office building in Bellevue in 2017. It's a growing, business-friendly city with great amenities, a high quality of life, and a fantastic talent pool. We now have more than 2,000 Amazonians working in Bellevue-and we continue to hire.Similar to Seattle, the City of Bellevue has a vision of a well-connected, walkable, and diverse 18-hour downtown core. This vision mirrors Amazon's commitment to its employees to provide a workplace that promotes well-being, accessibility, and innovation. After more than a year of partnership with Bellevue's urbanists, city planners, and real estate professionals, we are on track to create more than 15,000 new jobs in Bellevue over the next few years." Reference Link

11:25 EST Xbox's 'Gears' studio head Fergusson to join Blizzard to oversee 'Diablo' - Rod Fergusson, studio head at "Gears of War 4" and "Gears 5" developer The Coalition, announced via Twitter that he is leaving the company to join Blizzard (ATVI) to oversee the "Diablo" franchise. The Coalition is a subsidiary of Microsoft (MSFT). "Leaving is bittersweet as I love our Gears family, the fans, and everyone at The Coalition and Xbox," he said. "Thank you, it has been an honor and a privilege to work with you all." Reference Link

11:02 EST CBL Properties receives notification of non-compliance from NYSE - CBL Properties announced that it received notification from the New York Stock Exchange that as of February 5, 2020, the Company is no longer in compliance with NYSE continued listing criteria, which require listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period. The Company intends to pursue measures to cure the share price non-compliance. These measures include a reverse stock split of the Company's common stock, subject to approval by the Company's Board of Directors and stockholders, if such action is necessary to cure the share price non-compliance. In accordance with NYSE rules, the Company has a period of six months from receipt of the notice to regain compliance with the NYSE's minimum share price requirement. Under NYSE rules, the Company's common stock will continue to be listed and trade on the NYSE during this period, subject to the Company's compliance with other NYSE continued listing requirements. Under NYSE rules, CBL can regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the cure period, CBL's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period. The NYSE notification has no impact on CBL operations or its Securities and Exchange Commission reporting requirements, and it does not cause an event of default under any of the Company's material debt or other agreements.

10:42 EST Gores Holdings III (Units) trading halted, volatility trading pause

10:25 EST Norfolk Southern reports mainline derailment in Bound Brook, NJ - Norfolk Southern said in an emailed alert: "At approximately 6 a.m. EST Thursday, Feb. 6, Norfolk Southern experienced a mainline derailment in Bound Brook, New Jersey, approximately 30 miles west of Newark, New Jersey. Currently the route to and from north New Jersey, including Croxton and the Ports of New York, is out of service. Norfolk Southern is in the process of assessing the situation and will provide updates as conditions change. Customers with traffic moving through this area should anticipate a delay of 24 to 48 hours."

10:22 EST RMR Group management 'confident' there will be M&A announcement this FY

10:01 EST Leo Holdings Corp (Class A Stock) trading resumes

10:00 EST Spirit Airlines: Airbus delays likely to have larger impact in 2021 than 2020

10:00 EST ION Geophysical falls -23.6% - ION Geophysical is down -23.6%, or -$1.40 to $4.53.

10:00 EST Twitter rises 14.1% - Twitter is up 14.1%, or $4.70 to $38.09.

10:00 EST Muniholdings Florida Insured Fund V rises 40135.8% - Muniholdings Florida Insured Fund V is up 40135.8%, or $49.37 to $49.49.

09:54 EST Kellogg says will prioritize debt reduction over share repurchases in 2020 - Says will increase investments "meaningfully" in 2020 and they will be first half weighted.

09:46 EST Aura Minerals acknowledges reports on planning dual listing in Brazil - Aura Minerals announced that it is aware of media reports in Brazil that the company is planning on a dual listing by raising capital in the Brazilian Equity market. It said in a statement, "The Company is always evaluating alternatives with the aim of creating value for its shareholders. No determination to pursue any particular course of action has been made at this time. The Company will keep the market informed on a timely basis if any event or action which constitutes a material change in its affairs or material information occurs and in respect of which disclosure is necessary or advisable."

09:40 EST Spirit Airlines still sees CASM ex-fuel up 1%-2% in FY20

09:38 EST Kellogg says remained on strategy and on plan through 2019 - Says significantly restructured organization in 2019. Says can now sharpen focus on core businesses. Says expects "broad-based" sales growth in 2020, led by large brands. Comments taken from Q4 earnings conference call.

09:37 EST Spirit Airlines sees Q1 capacity up about 15% y/y

09:31 EST Leo Holdings Corp (Class A Stock) trading halted, news pending

09:28 EST Celsion announces DSMB confirms initial safety of weekly Gen-1 dosing - Celsion Corporation announced that the independent Data Safety Monitoring Board has completed its initial safety review of data from the first fifteen patients treated with the first four neoadjuvant doses of GEN-1 at 100 mg/m in the ongoing Phase I/II OVATION 2 Study. As requested by the U.S. Food and Drug Administration, a follow-on Phase 1 review by the DSMB will evaluate the safety of GEN-1 in up to 17 weekly doses before initiating the Phase 2 portion of the Study. The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy, a standard of care for newly diagnosed patients with Stage III and IV ovarian cancer. Following NACT, patients undergo interval debulking surgery followed by three additional cycles of chemotherapy. The OVATION 2 Study is an open label, 130 patient, 1 to 1 randomized Phase II trial, 80% powered to show the equivalent of a 33% improvement in progression-free survival, the primary endpoint, when comparing the treatment arm with the control arm. GEN-1, is a formulation of Celsion's proprietary, synthetic, non-viral cell transfection platform TheraPlas, incorporating, DNA plasmids coded for the inflammatory protein, interleukin-12. Cell transfection is followed by persistent, local secretion of the IL-12 protein, expected at therapeutic levels. The OVATION 2 Study builds on promising clinical and translational research data from the Phase IB OVATION I Study, in which enrolled patients received escalating weekly doses of GEN-1 for a total of eight treatments in combination with NACT, followed by IDS. These data from the OVATION I Study were presented at the ASCO-SITC Clinical-Oncology Symposium by Dr. Premal H. Thaker, M.D., M.S. on May 4, 2019 and can be reviewed here. In addition to exploring a higher dose of GEN-1 in the OVATION 2 Study, patients will continue to receive GEN-1 after their IDS in combination with adjuvant chemotherapy. The OVATION 2 Study is supported with promising clinical and translational data from the Company's prior Phase Ib OVATION I Study. In addition to a 100% objective response rate observed in all 9 patients at the two highest dose cohorts, translational research data demonstrates that GEN-1 is biologically active, producing therapeutic levels of IL-12 cytokines and positively impacting T-cell population in the tumor.

09:16 EST TOP Ships announces agreements to sell two product tankers - TOP Ships entered into agreements to sell, to unaffiliated third parties, two MR2 Product Tankers, the M/T Stena Weco Elegance and the M/T Eco Palm Desert. The sales are subject to customary closing conditions and are anticipated to be concluded within the first quarter of 2020.

09:10 EST Eastman Chemical appoints Charles Stevens to board of directors - The Board of Directors of Eastman Chemical Company (EMN) has elected Charles Stevens III as a director. Stevens is retired Executive Vice President and Chief Financial Officer of General Motors Company (GM).

09:08 EST Deutsche Bank shares jump after Capital Group's 3.1% stake revealed - Deutsche Bank shares are sharply higher after the bank disclosed in a filing earlier that The Capital Group Companies have acquired a new 3.1% stake in the company. "We are happy about the interest in our company, especially from shareholders with the track record and credibility of Capital," the bank said in a statement to Bloomberg following the stakeholding disclosure. In morning trading in New York, Deutsche Bank shares are up 85c, or 9.3%, to $9.96.

09:08 EST Foamix announces publication of Phase 3 studies evaluating FMX103 in JAAD - Foamix announced the publication of the company's Phase 3 studies FX2016-11 and FX2016-12 in the Journal of the American Academy of Dermatology. Studies 11 and 12 were conducted by Foamix to support the New Drug Application submission of FMX103, which is currently under review by the U.S. FDA for the treatment of moderate to severe papulopustular rosacea in adults. Both studies demonstrated high statistically significant superiority of FMX103 compared with vehicle in both primary endpoints of absolute inflammatory lesion reduction and Investigator's Global Assessment treatment success at Week 12 where approximately half of subjects achieved treatment success as defined by the latter endpoint. There was a statistically significant reduction in inflammatory lesions versus vehicle as early as Week 4 of treatment, and all subsequently assessed timepoints throughout the entire treatment course of the study. Subjects were no more likely to experience treatment-emergent adverse events from FMX103 than from vehicle treatment. The majority of TEAEs were mild to moderate. More than 95% of subjects using FMX103 had skin tolerability scores of none or mild at the treatment application site at Week 12. Specifically for erythema as part of skin tolerability assessments, 5.5% and 6.6% of subjects who received FMX103 in Studies 11 and 12 respectively, were assessed as being clear or almost clear at Baseline. At Week 12, 40.9% and 48.3% of subjects who received FMX103 respectively were assessed as clear or almost clear of erythema.

09:06 EST Comtech receives $1.2M contract for military Ku-band TWTAs - Comtech Telecommunications announced that during its Q2, its Santa Clara, California-based subsidiary, Comtech Xicom Technology, which is part of Comtech's Commercial Solutions segment, received a contract valued at $1.2M for Ka-band high-power traveling wave tube amplifiers, or TWTAs, for a military satellite communications ground system.

09:06 EST R.R. Donnelley announces partnership with Microsoft Store - R.R. Donnelley (RRD) is partnering with Microsoft (MSFT) Store to provide technology-supported, end-to-end creative and print collateral services, helping the retail brand enhance in-store engagement and react to market conditions. To ensure consistency while also being fast with its printed collateral, the retail brand needed a way to consolidate work for in-store signage across all Microsoft Store locations in the United States, Puerto Rico, and Canada. RRD is the first print studio for Microsoft Store that can print and use automation at large scale. Microsoft Store will utilize RRD's technology to automate sign-building workflows. The partnership between RRD and Microsoft Stores began in December 2019.

09:05 EST Comtech receives $1.3M contract for military Ku-band TWTA systems - Comtech Telecommunications announced that during its Q2, its Santa Clara, California-based subsidiary, Comtech Xicom Technology, which is part of Comtech's Commercial Solutions segment, received a contract valued at $1.3M for rack mounted Ku-band high-power traveling wave tube amplifier, or TWTA, systems for a military satellite communications ground system.

09:03 EST Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Twitter (TWTR), up 9%... Bristol-Meyers (BMY), up 3%... S&P Global (SPGI), up 3%... Regeneron (REGN), up 4%... Cigna (CI), up 3%... Cardinal Health (CAH), up 6%... Hain Celestial (HAIN), up 5%... Tapestry (TPR), up 2%. ALSO HIGHER: Unisys (UIS), up 42% after SAIC (SAIC) announced that it has entered into a definitive agreement to acquire the company, in an all-cash transaction valued at $1.2B. DOWN AFTER EARNINGS: Peloton (PTON), down 7%... Becton Dickinson (BDX), down 9%... Yum! Brands (YUM), down 4%... Tyson Foods (TSN), down 4%... Penn National (PENN), down 1%... Qualcomm (QCOM), down 2%. ALSO LOWER: TriState Capital (TSC), down 3% after 2.68M share spot secondary priced at $22.55... Perspecta (PRSP), down 20% after Wells Fargo analyst Ed Caso downgraded shares to Equal Weight from Overweight with a price target of $26, down from $31. The company was unsuccessful in its defense of the large "NGEN" contract with the U.S. Navy, which represented 15%-20% of revenue, Caso tells investors. The Navy deal was awarded to Leidos (LDOS)... Funko (FNKO), down 39% after pre-announcing worse than expected preliminary Q4 results.

09:01 EST IntercontinentalExchange: eBay wasn't interested in any deal ideas

08:59 EST IntercontinentalExchange Chairman: eBay 'not engaged with us' - Comments taken from Q4 earnings conference call.

08:54 EST Yum! Brands sees possible additional impact from Pizza Hut debt expense

08:50 EST Tapestry says to share plans of business review this summer

08:47 EST Conduent announces Maven platform to track coronavirus outbreak - Conduent announced a version of its disease surveillance and outbreak management platform, Maven, to securely track, manage and report on cases of the coronavirus, 2019-nCov. Maven is a software platform developed for organizations, including government agencies, to manage cases of more than 90 communicable diseases. Its flexible design gives organizations the capability to customize disease tracking most prevalent in specific geographies or communities. Conduent will host the platform's coronavirus-enabled version of Maven in the company's secure cloud so public health agencies and other organizations can get immediate access to use it. Conduent expects its coronavirus module to be available within the month. Additionally, those with advanced training also can leverage the solution's flexibility to customize the Maven platform on their own to track coronavirus. Based on an organization's need, Maven has the capability to track diseases such as influenza, tuberculosis and Ebola. More than 40 organizations are currently using Maven, and some have already taken advantage of the platform's flexibility by configuring it to track the coronavirus's spread within their respective locations. Conduent is also actively facilitating sharing of best practices between clients as they configure their systems to track the outbreak.

08:45 EST Twitter says 'pleased with engagement usage' - Says advertisers have "embraced our objectives." Says leaning towards more direct response products.

08:44 EST Amazon announces first Iowa fulfillment center - Amazon announced plans to open its first fulfillment center in the state of Iowa in the city of Bondurant. The site, which is anticipated to launch in late 2020, "will create 1,000 new full-time jobs with industry leading pay and comprehensive benefits starting on day one." At the new 645,000 square-foot fulfillment center employees will work alongside Amazon robotics to pick, pack and ship small items to customers such as books, electronics and toys. Amazon has also pledged to invest over $700 million to provide upskilling training for 100,000 U.S. employees for in demand jobs. Programs will help Amazonians from all backgrounds access training to move into highly skilled roles across the company's corporate offices, tech hubs, fulfillment centers, retails stores, and transportation network, or pursue career paths outside of Amazon.

08:42 EST Yum! Brands says long-term growth model remains unchanged - Management added the company may be below long-term financial goals in FY20, due to headwinds and impact from coronavirus.

08:39 EST Yum! Brands sees FY20 SSS up 2%-3% - Comments taken from Q4 earnings conference call.

08:39 EST New Frontier Health provides coronavirus update - New Frontier Health, operator of United Family Healthcare, or UFH, announced that UFH's seven operating hospitals and 18 clinics in China are well prepared to care for patients throughout the current challenges of the 2019 novel coronavirus, or 2019-nCoV, outbreak. UFH is among a handful of private healthcare operators in China designated by the Chinese government to operate fever care centers in its hospital facilities in order to combat the 2019-nCoV outbreak. In all UFH facilities, strict procedures are in place to limit cross contamination, to ensure escalation of fever cases, and to keep patients and staff safe in accordance with WHO and Chinese health authority guidelines. In each city where UFH operates, a UFH hospital facility has established fever care centers with separate and isolated areas in which to screen and test patients with fevers for potential infection by the 2019-nCoV virus. These fever screening centers are separated by air flows and work flows from standard patient clinics, emergency rooms, and inpatient facilities to keep any potentially infected patients from impacting other patients or visitors. As such, nearly all UFH facilities/ departments continue to offer services as needed for both inpatients and outpatients. NFH takes seriously its obligation to be continually available to the community it serves, and as such has made sure that it has adequate supplies to protect both its healthcare workers and patients. UFH is uniquely prepared among all private hospitals in China to address the outbreak, having had experience as a designated international screening center in Beijing during the SARS epidemic. As a result of UFH's depth of industry experience, international best practices, and committed workforce, UFH has provided training to its staff, adjusted patient flows, and procured appropriate supplies early in the process to meet the needs of the outbreak.

08:37 EST Tapestry: China represents 'significant' opportunity for brands - Comments taken from Q2 earnings conference call.

08:33 EST Curis and Aurigene amend collaboration agreement on NSCLC candidate - Curis has entered into an amendment of its collaboration, license and option agreement with Aurigene Discovery Technologies. Under the terms of the amended agreement, Aurigene will fund and conduct a Phase 2b/3 randomized study evaluating CA-170, an orally available, dual inhibitor of VISTA and PDL1, in combination with chemoradiation, in approximately 240 patients with non-squamous non-small cell lung cancer - nsNSCLC. In turn, Aurigene receives rights to develop and commercialize CA-170 in Asia, in addition to its existing rights in India and Russia, based on the terms of the original agreement. Curis retains U.S., E.U., and rest of world rights to CA-170, and is entitled to receive royalty payments on potential future sales of CA-170 in Asia. In 2019, Aurigene presented clinical data from a Phase 2a basket study of CA-170 in patients with multiple tumor types, including those with nsNSCLC. In the study, CA-170 demonstrated promising signs of safety and efficacy in nsNSCLC patients compared to various anti-PD-1/PD-L1 antibodies.

08:31 EST Twitter says advertiser sentiment 'remains strong' - Says expects to complete rebuild of ad server in 1H20. Says plans to work to improve ad response outside the U.S. Says continues to believe "revenue can grow faster than audience." Says has to build a company "not entirely dependent on San Francisco."

08:30 EST ForeScout Technologies trading resumes

08:27 EST Envision Solar says Glendale, Arizona orders first EV ARC charging product - Envision Solar International announced that the City of Glendale Arizona has placed their first order for the Company's EV ARC EV charging infrastructure product. The EV ARC will be used to charge Glendale's electric fleet vehicles.

08:24 EST Ekso Bionics releases upgraded EksoPulse platform - Ekso Bionics Holdings announced the worldwide launch of its upgraded EksoPulse platform, an innovative cloud-based information technology platform that measures and analyzes progress using the EksoNR robotic exoskeleton. The improved analytics system provides an easy-to-use dashboard to chart activity in rehabilitation sessions, enhancing the clinician, institutional, and patient experience of the most clinically used exoskeleton. The new EksoPulse platform technology uniquely allows physical therapists and physicians to track and personalize patient care with EksoNR. During rehabilitation sessions, EksoPulse captures important measures of patient progress, including the number of steps taken, the quality of steps, and how much assistance was given to a patient. The data is then synchronized via cellular technology and transmitted to Ekso's secure, cloud-based system. Users can view data stored on the secure EksoPulse system from any web browser to make informed decisions. Healthcare administrators can also use the portal to gauge overall usage of the EksoNR device in their facility. The upgraded EksoPulse platform is immediately available to rehabilitation centers around the world that are using the newest generation EksoNR with SmartAssist, a comprehensive gait therapy software. EksoGT users will have access to select new EksoPulse features, and have the option to upgrade to EksoNR, which allows full access to the new EksoPulse platform.

08:23 EST Euronet to provide Amazon India with transaction processing services - Euronet Worldwide (EEFT) announced it will provide integration and content aggregation services through APIs from its REV Payments Cloud to add mobile recharges, bill payments, gift cards, consumer software, and other offerings to Amazon India (AMZN). In addition to the transaction processing services, Euronet will also provide technology integration and reconciliation services for onboarding new billers and merchants onto the platform. The integration has already created an LPG cylinder booking category on Amazon with several more categories scheduled to launch in the coming months.

08:20 EST Dare Bioscience regains compliance with Nasdaq minimum equity rule - Dare Bioscience announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b). As a result, all previously reported Nasdaq compliance matters have been resolved and the previously-scheduled hearing before the Nasdaq Hearings Panel has been canceled. During January 2020, Dare raised approximately $5.1 million in net proceeds from the sale of approximately 3.1 million shares of its common stock under its at-the-market facility and received approximately $1.7 million from the exercise of approximately 1.7 million warrants. As a result of these activities, the Company's total shares of common stock outstanding increased to 24,513,675.

08:18 EST China Xiangtai Food reports 300% supermarket sales growth - China Xiangtai Food's supermarket sales grew 300% during Chinese New Year 2020 vs. the same period of last year despite of the ongoing 2019 Novel Coronavirus. To meet the public demand for food and to stabilize the pork price in the market, the company stated that it has increased its efforts to ease the negative impact of the 2019 Novel Coronavirus on food supplies.

08:16 EST Blueprint Medicines' avapritinib included as recommended in NCCN guidelines - Blueprint Medicines announced that the National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology - NCCN Guidelines - for Soft Tissue Sarcoma to include avapritinib as a recommended category 2A treatment for unresectable or metastatic GIST with a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, as well as fourth-line GIST. This rating indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Guidelines are the recognized clinical standard for cancer care by U.S. healthcare providers and payers, and are maintained by a committee of expert physicians from leading U.S. cancer centers.

08:15 EST Sanuwave Health completes offering, sees path to profitability in 2020 - SANUWAVE Health announced the completion of our follow on equity offering. The combined offerings have brought over $5 million of investment capital to the company between the December 2019 and January 2020 closes. The funding allows SANUWAVE a path to reach profitability later this year. The offering was led by new institutional investors.

08:14 EST Power REIT acquires three greenhouse properties for cultivation, processing - Power REIT announces that it has completed the acquisition of two greenhouse properties in southern Colorado through two wholly owned subsidiaries for $3.75 million. The acquisitions represent combined straight-line annual rent estimated to be approximately $700 thousand, which translates to an approximate 18.7% yield. The acquisitions complement Power REIT's existing high-quality real estate related to transportation infrastructure, alternative energy and Controlled Environment Agriculture. CEA uses innovative methods to grow plants in optimized indoor growing environments for a given crop. Power REIT intends to focus on CEA related real estate for growing various crops, including cannabis. As previously disclosed, Power REIT recently completed a $15.5 million debt financing at a rate of 4.62% which fully amortizes over a 35-year term. A portion of the funds were utilized to acquire the two aforementioned assets. In addition to these acquisitions, Power REIT has an extensive pipeline of CEA projects and is actively working to deploy the remainder of the capital available for investment. Concurrent with the closings on the acquisitions, Power REIT entered into "triple-net" leases that require each tenant to pay all property related expenses including maintenance, insurance and taxes. Each lease has a term of 20 years and provides two 5-year renewal options for the tenant with financial guarantees from affiliates of the tenant. The leases require each tenant to maintain a valid medical marijuana license and to operate in accordance with all Colorado and municipal regulations while prohibiting the retail sale of its products from the properties. Maverick 14 was acquired for $850 thousand. The 5.54-acre property has an existing greenhouse and processing facility totaling 8,300 square feet. As part of the transaction, Power REIT has agreed to fund the immediate expansion of 15,120 square feet of greenhouse space for approximately $1.1 million. The tenant has also agreed to fund the construction of an additional 2,520 square feet of processing space. Power REIT's total capital commitment is approximately $1.9 million. The property is located in the subdivision, which has been developed through an alliance with the existing tenant and developer who have extensive experience constructing greenhouses. An affiliate of the tenant has also received preliminary approval to operate a dispensary in the town where the properties are located. Sherman 6 was acquired for $150,000. The vacant land parcel is comprised of 5.0 acres, which has been approved for cannabis cultivation. As part of this transaction, the Trust has agreed to fund the immediate construction of 15,120 square feet of greenhouse space and 7,520 square feet of processing space on the property for approximately $1.7 million. Power REIT's total capital commitment is approximately $1.8 million. The Sherman 6 tenant is owned by an affiliate of a company that currently has three retail dispensaries in southern Colorado and operates an 18,000 square foot indoor cannabis growing facility that is on a short-term lease. Given current conditions, it is anticipated that product demand will far exceed its current production capacity.

08:12 EST White Gold intercepts significant gold values across White Gold property - White Gold Corp announced Rotary Air Blast drill results on multiple newly identified drill targets located across its White Gold property, in the prolific White Gold District, Yukon, Canada. Significant gold mineralization was encountered on several targets located in the area surrounding the Golden Saddle & Arc deposits. These targets were discovered through the Company's proprietary, data driven exploration strategy and include the McKinnon East, Ulli's Ridge, Minneapolis Creek and several other targets. The 2019 RAB drill program was designed to drill a limited number of holes per target as a preliminary evaluation of the target areas with preliminary drilling of the additional new targets and follow up to be performed in 2020. White Gold Corp's fully-funded $13 million 2019 exploration program backed by partners Agnico Eagle Mines Limited (AEM) and Kinross Gold Corp included diamond drilling on the Vertigo target, Golden Saddle & Arc deposits as well as soil sampling, prospecting, GT Probe, trenching and RAB/RC drilling on various other properties across the Company's expansive land package located in the prolific White Gold District, Yukon, Canada.

08:11 EST William Lyon Homes trading halted, news dissemination

08:09 EST Alnylam says current cash will support operations for 'multiple years' - FY20 financial guidance consists of the following: ONPATTRO net product revenues of $285 million - $315 million; Net revenues from collaborators of $100 million - $150 million; GAAP R&D and SG&A expenses of $1.18B-$1.3B; Non-GAAP R&D and SG&A expenses of $1.03B-$1.13B; The company expects that its current cash, cash equivalents, and marketable debt and equity securities will support company operations for multiple years based on its current operating plans.

08:09 EST Lineage Cell Therapeutics provides update on OpRegen study - Lineage Cell Therapeutics provided an update from its ongoing Phase I/IIa clinical study of OpRegen, the company's retinal pigment epithelium, or RPE, transplant therapy, for the treatment of dry age-related macular degeneration, or dry AMD. Dry AMD is a leading cause of adult blindness in the developed world with no FDA-approved treatment options. Based on preliminary results from the ongoing clinical study, including using Lineage's new thaw-and-inject formulation of OpRegen with Gyroscope Therapeutics' Orbit Subretinal Delivery System, the company has been informed by the study's independent data safety monitoring board that the protocol-mandated treatment stagger can be removed. In addition, Lineage is opening two new clinical sites to accelerate patient enrollment and broaden surgical experience among dry AMD experts. All five patients in Cohort 4, those with better baseline vision and which represent the company's intended patient population, have shown increases in best corrected visual acuity. Notably, the first Cohort 4 patient dosed with both the company's new thaw-and-inject formulation and Orbit subretinal delivery system, gained 25 readable letters at six months following administration of OpRegen RPE cells as assessed by the Early Treatment Diabetic Retinopathy Scale. This positive outcome represents an improvement in visual acuity from 20/250 to 20/100 in the patient's treated eye. There was no change in BCVA in the patient's untreated eye. To date, improvements have become most evident approximately three to six months after treatment with improvements in BCVA lasting at least 15 months with longer timepoints still to be collected. Safety data and evidence of successful engraftment of transplanted RPE cells is available for as long as three years in some patients. Because no unexpected complications have been observed with the new formulation and delivery system, the study's DSMB has removed the protocol-mandated enrollment stagger, which will permit Lineage to accelerate the rate of patient enrollment by opening additional clinical sites, as well as to treat patients with less advanced disease and smaller areas of geographic atrophy than patients in Cohort 1 through Cohort 3, which were legally blind due to more progressive disease. The company is opening two new clinical sites, Cincinnati Eye Institute and Wills Eye Hospital.

08:06 EST Twitter says 2019 was a 'great year' - Says has come "a long way" with improving infrastructure. Says misleading information is "biggest challenge" facing company and industry. Says will strive to have "a more distributed workforce." Comments taken from Q4 earnings conference call.

08:01 EST Scholar Rock presents data for SRK-015 at SMA Europe conference - Scholar Rock announced two poster presentations on SRK-015, a highly specific inhibitor of the activation of latent myostatin, at the SMA Europe 2nd International Scientific Congress being held in Paris-Evry, France. The two posters will highlight key preclinical and Phase 1 clinical data for SRK-015 as well as preliminary demographics, baseline characteristics, and pharmacokinetic/pharmacodynamic data from the TOPAZ Phase 2 proof-of-concept trial evaluating SRK-015 for the treatment of patients with Type 2 and Type 3 Spinal Muscular Atrophy. A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy: An Introduction. Preliminary TOPAZ demographic and baseline characteristics: Enrollment in the TOPAZ trial has been completed with a total of 58 patients enrolled across 19 sites in the U.S. and Europe; Cohort 1 enrolled 23 patients with ambulatory Type 3 SMA; Cohort 2 enrolled 15 patients with Type 2 or non-ambulatory Type 3 SMA; Cohort 3 enrolled 20 patients with Type 2 SMA; Preliminary demographic and baseline characteristic data are in-line with published data with nusinersen and ensure appropriate inclusion of patients with Type 2 and Type 3 SMA. Mean age at informed consent was 12.7 years in Cohort 1, 11.8 years in Cohort 2, and 4.0 years in Cohort 3. Mean Revised Hammersmith Scale score at screening in Cohort 1 was 47.4 Mean Hammersmith Functional Motor Scale Expanded score at screening in Cohort 2 and 3 were 22.5 and 24.8, respectively. Preliminary PK/PD analysis: Preliminary PK/PD analysis of the TOPAZ trial includes data from 29 patients across the three cohorts; 12 patients in Cohort 1, eight patients in Cohort 2, and nine patients in Cohort 3. These patients had received one dose of SRK-015 and were evaluated for four weeks as of the data cutoff. Dose-dependent increases of up to 100-fold in serum latent myostatin levels following treatment with SRK-015 confirms the presence of latent myostatin in patients with SMA and demonstrates robust target engagement. Fold-increases from baseline in serum latent myostatin levels in the first four weeks following SRK-015 treatment were comparable between SMA patients in the TOPAZ trial and healthy adult volunteers in the Phase 1 trial. In patients with SMA, SRK-015 displayed a preliminary PK profile exhibiting dose proportionality and low variability, consistent with PK observations from the Phase 1 trial in healthy adult volunteers. No clinically significant safety signals had been observed as of the data cutoff for this preliminary PK/PD analysis. Preclinical and Phase 1 Healthy Volunteer Clinical Data: Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy. Preclinical studies: Improved muscle strength following administration of muSRK-015P in mouse models of early and late SMN restoration. Treatment with muSRK-015P resulted in 20%-51% increases in maximal torque of the plantar flexor muscle group and a greater percentage of muscle fibers compared to treatment with placebo. Multi-fold increase in serum latent myostatin levels following treatment with muSRK-015P in both early and late SMN restoration mouse models confirm the presence of the latent myostatin target in a modeled diseased setting. Relative dose-proportional accumulation of serum latent myostatin, demonstrating target engagement, in rats and cynomolgus monkeys following administration of SRK-015 compared to no meaningful change with placebo. Well-behaved pharmacokinetic profile displayed across animal species. Phase 1 healthy volunteer trial: SRK-015 was well-tolerated with no apparent safety signals and no dose-limiting toxicities were identified up to the highest evaluated dose of 30 mg/kg. Robust and sustained target engagement, along with durable saturation, following administration of SRK-015 in both the single-ascending and multiple-ascending dose portions of the Phase 1 trial. Well-behaved PK profile, supporting dosing once every 4-weeks, which is being evaluated in the ongoing Phase 2 trial.

07:53 EST J.C. Penney announces denim collection with assortment of Honestly Good Jeans - JCPenney is unfolding a new assortment of jeans with a complete reimagination of its a.n.a brand, focused on the denim customers love and a size-inclusive selection for all body shapes and sizes. The brand's new look is the result of extensive customer research and establishes a.n.a as the Company's denim lifestyle brand for women. Under the direction of Michelle Wlazlo, executive vice president and chief merchant, the Company has been focused on strengthening its iconic private brands according to the five lifestyles that resonate with customers and how they want to shop: Move, Chill, All Day, On Point, and Shine. New a.n.a products were created by experienced, in-house JCPenney product and design teams, who utilized real-time customer feedback to ensure the selection is nothing short of what denim shoppers want. The expanded collection touts Honestly Good Jeans, with 15 fits in more than 80 washes in missy, petite, plus, and tall categories. Sizes 2-24W will be available February 6 in stores and the JCPenney flagship store, jcp.com, with the full online assortment carrying sizes 2-30W and tall sizing available March 1.

07:42 EST Guardion Health Sciences announces development of immuno-supportive complex - Guardion Health Sciences announced the development of a unique proprietary formulation to provide immuno-support and anti-inflammatory benefits targeting the upper respiratory tract. The Company's efforts are being spearheaded by its recently acquired NutriGuard business line. NutriGuard formulates high-quality, scientifically-credible, condition-specific nutraceuticals designed to supplement consumers' diets and assist in the prevention and management of an array of diseases and conditions. This proprietary new product, to be preliminarily labeled acuMMUNE, was designed by Guardion's internal product and technology design team, and is the first product to be introduced by Guardion under the NutriGuard label. The acuMMUNE formulation was designed with the objective of supporting effective immune function - including, in particular, interferon-mediated anti-viral mechanisms - while also mitigating the excessive lung inflammation that can lead to the harsh symptoms and even death caused by severe lung infections associated with certain viral infections. acuMMUNE will initially be offered in a capsule form and will be available in the United States through the Company's web-site. The Company is currently in the process of arranging for the manufacture and packaging of acuMMUNE at contract facilities in the United States and expects that this product will be available for sale beginning in approximately April 2020. The Company anticipates that acuMMUNE will also be available for export to various international markets shortly thereafter.

07:37 EST Intercontinental Exchange raises quarterly dividend by 9% to 30c per share - Intercontinental Exchange announced board authorization of its Q1 dividend of 30c per share, up 9% from its previous 27.5c per share quarterly dividend in 2019. The first quarter cash dividend is payable on March 31, to stockholders of record as of March 17. The ex-dividend date is March 16.

07:37 EST IntercontinentalExchange reports new $2.4B share repurchase program - Intercontinental Exchange announced a new $2.4B share repurchase program effective January 1, 2020. ICE repurchased $1.5B of its common stock and paid $621M in dividends in 2019.

07:34 EST Brink's announces $250M share repurchase authorization - The Brink's Company announced that its board of directors authorized a $250M share repurchase authorization that expires on December 31, 2021. The authorization replaces the company's previous share repurchase program, which expired December 31, 2019. Under the previous program, Brink's repurchased 1.3 million shares of its common stock for approximately $94 million, or an average cost of $69.35 per share. The timing and volume of share repurchases may be executed at the discretion of management on an opportunistic basis, or pursuant to trading plans or other arrangements. Any share repurchase under this program may be made in the open market, in privately negotiated transactions, or otherwise. The share repurchase program may be suspended or discontinued at any time.

07:34 EST Tyson Foods sees FY20 adjusted tax rate around 23.5% - "For fiscal 2020, we expect capital expenditures to be approximately $1.3 billion. Capital expenditures will include spending for production growth, safety, animal well-being, infrastructure replacements and upgrades, and operational improvements that are expected to result in production and labor efficiencies, yield improvements and sales channel flexibility. We expect net interest expense to approximate $450 million for fiscal 2020." Tyson also said it expects industry fed cattle supplies to increase approximately 1% in fiscal 2020 as compared to fiscal 2019. "We expect ample supplies in regions where we operate our plants. For fiscal 2020, we believe our Beef segment's adjusted operating margin will be toward the upper end of 6.5% to 7.5%, absent additional impacts from ASF. We expect industry hog supplies to increase approximately 4% in fiscal 2020 as compared to fiscal 2019. We expect increased livestock costs in fiscal 2020 as compared to fiscal 2019. For fiscal 2020, we believe our Pork segment's adjusted operating margin will be 6% to 8%, absent additional impacts from ASF. USDA projects a 4% increase in chicken production in fiscal 2020 as compared to fiscal 2019. For fiscal 2020, we believe our Chicken segment's adjusted operating margin will be 4% to 6%, absent additional impacts from ASF. We expect raw material costs to increase throughout fiscal 2020 as compared to fiscal 2019, but we expect to recover these costs through pricing over time. Given the timing lag on passing these prices through, we may not fully recover these costs within the fiscal year. For fiscal 2020, we believe our Prepared Foods segment's adjusted operating margin will be 10% to 12%."

07:30 EST Brainsway Ltd (ADS) trading resumes

07:25 EST BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of BioCryst common stock on January 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.85 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

07:25 EST Strategy Analytics: Apple Watch outsold entire Swiss watch industry in 2019 - The Apple Watch outsold the entire Swiss watch industry in 2019, according to a report from Strategy Analytics. Strategy Analytics estimates that Apple shipped 30.7 million units worldwide of its smartwatch last year, compared to 21.1 million for all Swiss watch brands combined. "Analog wristwatches remain popular among older consumers, but younger buyers are tipping toward smartwatches and computerized wristwear," Strategy Analytics said in its report. Reference Link

07:22 EST Aquestive Therapeutics announced FDA confirmed pathway for AQST-108 - Aquestive Therapeutics announced that it had a constructive face-to-face pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate, AQST-108, a "first of its kind" oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive's proprietary PharmFilm technologies. A pre-IND meeting provides an opportunity for an open communication between a drug sponsor and the FDA to discuss the sponsor's IND development plan and to obtain the agency's guidance for clinical studies for the sponsor's new drug candidate. The FDA has confirmed that the clinical development for AQST-108 will be reviewed under the 505(b)(2) pathway as proposed by Aquestive and that no additional studies would be necessary prior to opening the proposed IND Application. The FDA indicated that there appears to be an unmet medical need among patients who resist the standard of care use of intramuscular injection in the treatment of anaphylaxis and that AQST-108 may potentially address some of those unmet needs. Aquestive plans to move forward with opening an IND and initiating its pivotal pharmacokinetic clinical trials before the end of 2020.

07:21 EST New York Times sees Q1 subscription revenues up mid-single digits - Total advertising revenues in Q1 are expected to decline approximately 10%, with digital advertising revenue expected to decrease in the mid-single digits. Other revenues in Q1 are expected to increase approximately 15%. Operating costs and adjusted operating costs in Q1 are expected to increase approximately 5%-7%.

07:20 EST Philip Morris sees FY20 CapEx approximately $1B - Sees FY20: Operating cash flow of approximately $10.5 B, subject to year-end working capital requirements and currency movements; An effective tax rate of approximately 23.0%; and no share repurchases.

07:17 EST Brainsway to discontinue funding of H7 Deep TMS study in PTSD - BrainsWay announced interim results from a multicenter randomized controlled double-blind clinical trial assessing the safety and efficacy of the Company's H7-coil deep transcranial magnetic stimulation System for the treatment of adults with post-traumatic stress disorder. Results showed that the H7 dTMS, which targets the medial prefrontal cortex, did not demonstrate sufficient efficacy relative to sham control treatment in PTSD patients. Based on the interim analysis, the Company will not invest additional resources in order to continue this study. BrainsWay is performing additional analysis and will consider future PTSD studies using alternative parameters. The study utilized the Company's H7-coil, one of BrainsWay's proprietary coils, to target the mPFC, which has traditionally been associated with PTSD symptoms. The study was a randomized double-blind multicenter study, designed to evaluate the safety and efficacy of H7 dTMS treatment in reducing symptoms in individuals suffering from PTSD. The trial was conducted at 16 clinical sites, including leading academic institutions, primarily in the United States. Subjects received either H7 dTMS or sham treatment over the course of four weeks, with two booster sessions at weeks five and nine. For both the active and sham groups, treatments were administered following tailored symptom provocation in the form of a pre-prepared audio recording of a script of the traumatic event. The primary endpoint was a comparison between active and sham treatment groups of the change in CAPS-5 score from baseline to week five. The interim analysis was conducted on the first 87 eligible subjects who completed the study protocol, and it revealed a significant reduction of PTSD symptoms in both the active and sham groups. The clinical benefit observed in the sham group may possibly be explained by the brief exposure therapy as part of the tailored provocation. However, the results did not demonstrate sufficient clinical benefit induced specifically by the active treatment to justify continuation of the trial. Overall, the treatment was found to be well-tolerated by participants in the study and no seizures were reported. There were no serious adverse events reported in the study related to the device. "We are disappointed with the outcome of the interim analysis, and believe discontinuing the trial at this time is the best course of action as we reevaluate our options with this very complex mental health condition," said Christopher R von Jako, Ph.D., President and CEO of BrainsWay. "We remain focused on executing our growth strategy through our current FDA-cleared indications of Major Depressive Disorder and Obsessive Compulsive Disorder, which represents an addressable market of approximately $9 billion. In addition, we continue to maintain a robust pipeline of additional applications with our proprietary dTMS platform targeted at other large-market psychiatric, neurological, and addiction conditions."

07:17 EST Arconic board approves separation of company

07:15 EST Cato Corp. reports January SSS up 1% - The Cato Corporation reported sales for the four weeks ended February 1, 2020 of $44.2M, down 1% compared to sales of $44.5M for the four week period ended February 2, 2019. Same-store sales for January were up 1% compared to the four weeks ended February 2, 2019. Sales for fiscal fourth quarter ended February 1, 2020 were $188.2M, a decrease of 1% from sales of $190.4N for the fourth quarter ended February 2, 2019. For the quarter, same-store sales increased 1% to last year. For the year, the company's sales decreased 1% to $816M from 2019 sales of $821.2M. For the year, same-store sales increased 2% over last year.

07:13 EST GasLog declares special dividend of 38c per common share

07:11 EST The Buckle reports January SSS up 7.4% - January net sales iincreased 3.2% to $47.2M from net sales of $45.8M for January 2019.

07:10 EST GasLog Partners increase amount available under repurchase authority to $25M - On January 29, 2019, the board of directors of GasLog Partners authorized a unit repurchase programme of up to $25.0 million covering the period from January 31, 2019 to December 31, 2021. Under the terms of the repurchase programme, GasLog Partners may repurchase common units from time to time, at its discretion, on the open market or in privately negotiated transactions. In the three months ended December 31, 2019, GasLog Partners repurchased and cancelled 186,313 of the Partnership's common units at a weighted average price of $15.33 per common unit for a total amount of $2.9 million, including commissions. Since the authorization of the unit repurchase programme and through February 6, 2020, GasLog Partners has repurchased and cancelled a total of 1,171,572 units at a weighted average price of $19.52 per common unit for a total amount of $22.9 million, including commissions. On February 5, 2020, the board of directors of GasLog Partners authorized a renewal of the unit repurchase programme in an amount of $23.0 million taking the total authority outstanding under the programme to $25.0 million which may be utilized from February 10, 2020 to December 31, 2021.

07:09 EST Bristol-Myers announces new $5B stock buyback - The company announced that its board of directors approved an increase of $5B to the share repurchase authorization for the company's common stock. This is incremental to the current share repurchase program announced in October 2016 under which the company has approximately $1B remaining and increases the company's total outstanding share repurchase authorization under the company's share repurchase program to approximately $6B.

07:08 EST Twitter sees growing headcount by 20% or more in 2020 - Twitter said: "As we enter 2020, we are focused on four objectives to drive our work. These are similar to previous years, and our success will best be measured externally by our ability to grow our audience and deliver financial results in line with our guidance. Our company objectives are: Increasing development velocity and trust; Increasing healthy public conversation ; Increasing revenue durability; Enabling anyone, anywhere to work at Twitter. To support these objectives, we expect to grow headcount by 20% or more in 2020, especially in engineering, product, design, and research. Given investment decisions made in previous years and anticipated 2020 headcount growth, we expect total costs and expenses (which include cost of revenue and all operating expenses) to grow approximately 20% in 2020, ramping in absolute dollars over the course of the year. Our investments also include building out a new data center in 2020 to add capacity to support audience and revenue growth. While the timing of these investments will be variable and spread out over multiple quarters, we expect capital expenditures to be weighted toward the second half of the year."

07:06 EST Xylem raises quarterly dividend 8%

07:05 EST Fiat Chrysler reports FY19 worldwide combined shipments 4.418M units - Reports worldwide combined shipments of 4,418 thousand units, down 9%, primarily due to dealerstock reduction in North America, lower China JV shipments along with sales channel actions and discontinuation of products in EMEA.

07:04 EST Fiat Chrysler reports FY19 adjusted EBIT EUR6.668B - Reports FY19 adjusted EBIT margin 6.2%.

07:01 EST GrafTech sees FY20 CapEx $60M-$70M

06:55 EST Brainsway Ltd (ADS) trading halted, news pending

06:47 EST SAIC to acquire Unisys Federal for $1.2B in cash - Science Applications International Corp. (SAIC) announced that it has entered into a definitive agreement to acquire Unisys Federal, in an all-cash transaction valued at $1.2B, in a highly strategic and value creating transaction, the company said. This represents a transaction multiple of approximately 10.5x CY2020 adjusted EBITDA, adjusted for the net present value of tax assets. Unisys Federal, an operating unit of Unisys (UIS), is a provider of infrastructure modernization, cloud migration, managed services, and enterprise IT-as-a-service through scalable and repeatable solutions to U.S. federal civilian agencies and the Department of Defense. SAIC expects to fund the $1.2B cash transaction through a combination of cash on hand and incremental debt. The transaction is expected to close by the end of SAIC's first quarter of fiscal year 2021, ending May 1, 2020, following customary closing conditions, including HSR regulatory clearance. The transaction has been unanimously approved by SAIC's Board of Directors. The businesses will continue to operate independently until the transaction closes. "With the addition of Unisys Federal, SAIC will be a leading provider of digitial transformation services and solutions to the federal government. This exciting opportunity advances our strategy by building on our modernization capabilities, increasing customer access, accelerating growth and enhancing shareholder value," said SAIC CEO Nazzic Keene. "The financial benefits of acquiring Unisys Federal are compelling, including accretion of adjusted EBITDA margins, non-GAAP earnings per share, and cash generation."

06:45 EST SAIC to acquire Unisys Federal for $1.2B in cash - Science Applications International Corp. (AIC) announced that it has entered into a definitive agreement to acquire Unisys Federal, in an all-cash transaction valued at $1.2B, in a highly strategic and value creating transaction. This represents a transaction multiple of approximately 10.5x CY2020 adjusted EBITDA, adjusted for the net present value of tax assets. Unisys Federal, an operating unit of Unisys (UIS), is a leading provider of infrastructure modernization, cloud migration, managed services, and enterprise IT-as-a-service through scalable and repeatable solutions to U.S. federal civilian agencies and the Department of Defense. SAIC expects to fund the $1.2B cash transaction through a combination of cash on hand and incremental debt. The transaction is expected to close by the end of SAIC's first quarter of fiscal year 2021, ending May 1, 2020, following customary closing conditions, including HSR regulatory clearance. The transaction has been unanimously approved by SAIC's Board of Directors. The businesses will continue to operate independently until the transaction closes.

06:43 EST Correction: SAIC to acquire Unisys Federal for $1.2B in cash

06:41 EST SAIC to acquire Unisys in all-cash transaction valued at $1.2B - Science Applications International Corp. (SAIC) announced that it has entered into a definitive agreement to acquire Unisys Federal (UIS), in an all-cash transaction valued at $1.2B, in a highly strategic and value creating transaction. This represents a transaction multiple of approximately 10.5x CY2020 adjusted EBITDA, adjusted for the net present value of tax assets. SAIC expects to fund the $1.2B cash transaction through a combination of cash on hand and incremental debt. The transaction is expected to close by the end of SAIC's first quarter of fiscal year 2021, ending May 1, 2020, following customary closing conditions, including HSR regulatory clearance. The transaction has been unanimously approved by SAIC's Board of Directors. The businesses will continue to operate independently until the transaction closes.

06:36 EST Arch Coal sees FY20 total sales volume 82.8M-87.2M tons - "Heading into 2020, we are sharply focused on demonstrating continued operational excellence across our entire mine portfolio while advancing our well-defined strategy for long-term value creation and growth," Eaves said. "We are driving forward with our efforts to further reduce the cost structure of our metallurgical segment; enhance our metallurgical portfolio's already significant cash-generating capabilities through the build-out of Leer South; generate significant levels of cash at our low-cost thermal assets; prepare those assets for an increasingly challenging market environment through the completion of the synergistic joint venture with Peabody; and maintain our industry-leading balance sheet strength. In short, we are working aggressively to strengthen our performance across a range of significant operational and financial metrics in our ongoing efforts to maximize long-term value creation for our shareholders."

06:31 EST Lumber Liquidators announces resignation of CEO Dennis Knowles

06:29 EST U.S. Xpress Enterprises sees slow truckload shipment growth in 2020 - U.S. Xpress' baseline assumptions for 2020 include slow growth in industry-wide truckload shipments, a continued reduction of total truckload capacity from the market, which is expected to drive an inflection in pricing later in the year, and relatively benign cost inflation. Q1 is generally its weakest quarter of the year as it experiences lower revenue per tractor and higher costs than the other quarters due to seasonal freight fluctuations and harsher operating conditions. While it sees positive trends in certain areas, there continues to be uncertainty in the short-term environment, which will impact the actual sequential margin deterioration in Q1. The company continues to believe that market conditions will improve in the back half 2020. The timing and magnitude of market changes will have a significant impact on quarterly results.

06:24 EST Melco to focus on core operations due to impact of travel restrictions to Macau - Melco Resorts & Entertainment announces that due to the impact of the coronavirus epidemic, including the severe drop in tourism in Asia to Integrated Resort, or IR, facilities in the region, and the recent decision by the Macau SAR government to close all casinos in Macau, Melco has taken the decision to reassess all non-core investments to be made in 2020. This decision reflects Melco's commitment towards its employees, customers, business partners and other stakeholders and observance of the highest degree of responsibility until such time as the global health emergency and the related travel restrictions that affect a significant part of its customer base are lifted. Melco considers its core operations to be those businesses where it is the managing and majority shareholder. This includes operations in Macau, the Philippines, and Cyprus and its efforts to obtain a license to operate a Melco-owned IR in Japan. Melco intends to continue its operations in these jurisdictions and carry out key investments currently earmarked for Macau, Manila, Cyprus, and Japan, including the construction of Studio City phase 2 and City of Dreams Mediterranean. Management attention will remain focused on these critical areas of Melco's business until such time as operations and business throughout Asia have returned to normal. As a result of this decision, Melco will not pursue its planned investment in Australia for the second tranche of shares in Crown Resorts. While Melco believes Crown has world-class assets that are complementary to its global business, it is Melco's belief that, at this time, its capital needs to be deployed on its core assets. CPH Crown Holdings Pty Limited and Melco have agreed to terminate the obligation to purchase the second tranche of Crown shares under the purchase agreement announced by the company on May 30, 2019 and amended on August 28, 2019. As a result of the termination, while Melco currently holds 67.68M shares of Crown, it will no longer acquire the remaining 67.68M shares of Crown. Melco does not currently intend to increase its existing shareholding in Crown from its current position. Melco also does not intend to seek representation on Crown's board.

06:18 EST Cellcom Israel announces potential frequency transfer - Cellcom Israel announced that following the company's previous reports regarding a frequencies migration thecCompany shall be required to execute by March 2021, to accord to European standards, the Ministry of Communications, or MOC, notified the company that it is considering the following alternative to its previous instruction: The company's current 2x10 850MHZ frequencies will be reduced and replaced with other 2x5 MHz 850MHZ frequencies no later than May 31; at a later date to be determined, the company will be awarded 2x5 MHz in the 800 frequencies; at a later date to be determined, the aforesaid 850MHz and 800MHz frequencies will be replaced with other 2x10 MHz in the 800 frequencies. The MOC will further consider allocating partial 800MHz or 900 MHz frequencies tender revenues, if such tenders are executed, to expedite such frequencies replacement. The MOC may further allocate to the company additional frequencies for limited periods during the transition period. The proposed alternative may result in an adverse effect on cellular service quality and ability to comply with quality standards set in our license and may have an adverse effect on our results of operations.

06:04 EST Prestige Brands sees FY20 adjusted free cash flow $200M or more

05:56 EST Cytokinetics announces publication relating to design of GALACTIC-HF - Cytokinetics announced the publication of a manuscript relating to the design of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil in the Journal of American College of Cardiology: Heart Failure. Omecamtiv mecarbil, a selective cardiac myosin activator, is being developed for the potential treatment of heart failure with reduced ejection fraction under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier. "GALACTIC-HF is not only one of the largest clinical trials of heart failure ever conducted but it has been designed to enroll a population of heart failure patients who are at high risk for cardiovascular events despite receiving standard of care therapies," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President, Research and Development. "This publication outlines key design elements of the trial including the statistical hypotheses being tested. We look forward to the second interim analysis of GALACTIC-HF later in this quarter and the final results from this clinical trial later this year."